Kana Tsuchimoto
Overview
Explore the profile of Kana Tsuchimoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
55
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamasaki M, Saso W, Yamamoto T, Sato M, Takagi H, Hasegawa T, et al.
Antiviral Res
. 2024 Aug;
230:105992.
PMID: 39181215
Given the worldwide risk for the outbreak of emerging/re-emerging respiratory viruses, establishment of new antiviral strategies is greatly demanded. In this study, we present a scheme to identify gapmer antisense...
2.
Hishiki T, Morita T, Akazawa D, Ohashi H, Park E, Kataoka M, et al.
Microbiol Spectr
. 2023 Jul;
11(4):e0056623.
PMID: 37409948
Mpox virus (formerly monkeypox virus [MPXV]) is a neglected zoonotic pathogen that caused a worldwide outbreak in May 2022. Given the lack of an established therapy, the development of an...
3.
Akazawa D, Ohashi H, Hishiki T, Morita T, Iwanami S, Kim K, et al.
J Infect Dis
. 2023 Mar;
228(5):591-603.
PMID: 36892247
Background: Mpox virus (MPXV) is a zoonotic orthopoxvirus and caused an outbreak in 2022. Although tecovirimat and brincidofovir are approved as anti-smallpox drugs, their effects in mpox patients have not...
4.
Ohashi H, Hishiki T, Akazawa D, Kim K, Woo J, Shionoya K, et al.
Antiviral Res
. 2022 Jul;
205:105372.
PMID: 35798223
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant BA.2 has spread in many countries, replacing the earlier Omicron subvariant BA.1 and other variants. Here, using a cell culture...
5.
Saso W, Yamasaki M, Nakakita S, Fukushi S, Tsuchimoto K, Watanabe N, et al.
PLoS Pathog
. 2022 Jun;
18(6):e1010590.
PMID: 35700214
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been transmitted across all over the world, in contrast to the limited epidemic of genetically- and virologically-related SARS-CoV. However, the molecular basis...
6.
Ohashi H, Wang F, Stappenbeck F, Tsuchimoto K, Kobayashi C, Saso W, et al.
Int J Mol Sci
. 2021 Apr;
22(6).
PMID: 33808940
The development of effective antiviral drugs targeting the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) is urgently needed to combat the coronavirus disease 2019 (COVID-19). We have previously studied the...